Nature Communications (Apr 2020)
Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction
- Mingzhu Yin,
- Ying Guo,
- Rui Hu,
- Wesley L. Cai,
- Yao Li,
- Shiyao Pei,
- Hongyin Sun,
- Cong Peng,
- Jiali Li,
- Rui Ye,
- Qiaohong Yang,
- Nenghui Wang,
- Yongguang Tao,
- Xiang Chen,
- Qin Yan
Affiliations
- Mingzhu Yin
- Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University
- Ying Guo
- Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University
- Rui Hu
- Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University
- Wesley L. Cai
- Department of Pathology, Yale School of Medicine
- Yao Li
- Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University
- Shiyao Pei
- Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University
- Hongyin Sun
- Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University
- Cong Peng
- Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University
- Jiali Li
- Department of Pathology, Yale School of Medicine
- Rui Ye
- Department of Pathology, Yale School of Medicine
- Qiaohong Yang
- School of Basic Medical Sciences, Guangzhou University of Chinese Medicine
- Nenghui Wang
- Ningbo Wenda Pharma, Ninghai
- Yongguang Tao
- Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Xiangya Hospital, Central South University
- Xiang Chen
- Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University
- Qin Yan
- Department of Pathology, Yale School of Medicine
- DOI
- https://doi.org/10.1038/s41467-020-15290-0
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 14
Abstract
Inhibitors of the BET family proteins are limited by their potency and oral bio-availability. Here, the authors report a new BET inhibitor, NHWD-870, with improved potency compared to previous BET inhibitors, and show that it suppresses BRD4 and targets tumour associated macrophages.
